IL122123A - Estrogen agonists / antagonists, their pharmaceutical preparations and their use in the preparation of drugs for the treatment of atherosclerosis - Google Patents

Estrogen agonists / antagonists, their pharmaceutical preparations and their use in the preparation of drugs for the treatment of atherosclerosis

Info

Publication number: IL122123A
Authority: IL; Israel
Prior art keywords: phenyl; compound; recited; independently selected; formula
Prior art date: 1996-11-15

Application number

IL12212397A

Other languages

English (en)

Hebrew (he)

Other versions

IL122123A0 (en

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-15

Filing date

1997-11-06

Publication date

2001-07-24

1997-11-06 Application filed by Pfizer filed Critical Pfizer

1998-04-05 Publication of IL122123A0 publication Critical patent/IL122123A0/xx

2001-07-24 Publication of IL122123A publication Critical patent/IL122123A/en

Links

201000001320 Atherosclerosis Diseases 0.000 title claims abstract description 18
238000002360 preparation method Methods 0.000 title claims description 10
239000003814 drug Substances 0.000 title claims description 8
229940011871 estrogen Drugs 0.000 title description 8
239000000262 estrogen Substances 0.000 title description 8
239000000556 agonist Substances 0.000 title description 7
239000005557 antagonist Substances 0.000 title description 5
150000001875 compounds Chemical class 0.000 claims abstract description 105
125000001424 substituent group Chemical group 0.000 claims abstract description 56
230000003902 lesion Effects 0.000 claims abstract description 39
150000002632 lipids Chemical class 0.000 claims abstract description 29
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 25
125000005842 heteroatom Chemical group 0.000 claims abstract description 23
125000000623 heterocyclic group Chemical group 0.000 claims abstract description 20
230000002401 inhibitory effect Effects 0.000 claims abstract description 19
241000124008 Mammalia Species 0.000 claims abstract description 18
238000011282 treatment Methods 0.000 claims abstract description 17
230000000087 stabilizing effect Effects 0.000 claims abstract description 14
230000000923 atherogenic effect Effects 0.000 claims abstract description 13
-1 bicyclic amine Chemical class 0.000 claims abstract description 11
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 11
150000003839 salts Chemical class 0.000 claims abstract description 11
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 10
231100000252 nontoxic Toxicity 0.000 claims abstract description 7
230000003000 nontoxic effect Effects 0.000 claims abstract description 7
150000001204 N-oxides Chemical class 0.000 claims abstract description 6
239000002253 acid Substances 0.000 claims abstract description 6
150000002148 esters Chemical class 0.000 claims abstract description 6
125000001624 naphthyl group Chemical group 0.000 claims abstract description 6
230000003287 optical effect Effects 0.000 claims abstract description 6
150000003242 quaternary ammonium salts Chemical class 0.000 claims abstract description 6
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 5
229910052799 carbon Inorganic materials 0.000 claims abstract description 5
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 5
125000004070 6 membered heterocyclic group Chemical group 0.000 claims abstract description 4
125000000392 cycloalkenyl group Chemical group 0.000 claims abstract description 4
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract 3
125000000217 alkyl group Chemical group 0.000 claims description 22
230000014509 gene expression Effects 0.000 claims description 16
230000005764 inhibitory process Effects 0.000 claims description 14
229910052739 hydrogen Inorganic materials 0.000 claims description 12
239000001257 hydrogen Substances 0.000 claims description 12
102000019034 Chemokines Human genes 0.000 claims description 9
108010012236 Chemokines Proteins 0.000 claims description 9
125000003545 alkoxy group Chemical group 0.000 claims description 9
210000004969 inflammatory cell Anatomy 0.000 claims description 9
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
229910052736 halogen Inorganic materials 0.000 claims description 8
150000002367 halogens Chemical class 0.000 claims description 8
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
238000000034 method Methods 0.000 claims description 8
125000002837 carbocyclic group Chemical group 0.000 claims description 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
230000006641 stabilisation Effects 0.000 claims description 5
238000011105 stabilization Methods 0.000 claims description 5
125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 claims description 4
125000004423 acyloxy group Chemical group 0.000 claims description 4
125000003282 alkyl amino group Chemical group 0.000 claims description 4
125000004414 alkyl thio group Chemical group 0.000 claims description 4
125000003118 aryl group Chemical group 0.000 claims description 4
125000004663 dialkyl amino group Chemical group 0.000 claims description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
229920006395 saturated elastomer Polymers 0.000 claims description 4
125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 3
JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 claims description 3
206010061218 Inflammation Diseases 0.000 claims description 2
230000006041 cell recruitment Effects 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
230000004054 inflammatory process Effects 0.000 claims description 2
230000003859 lipid peroxidation Effects 0.000 claims description 2
230000008569 process Effects 0.000 claims description 2
GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 claims 4
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 1
125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
241000699670 Mus sp. Species 0.000 description 16
230000000694 effects Effects 0.000 description 16
210000001616 monocyte Anatomy 0.000 description 14
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 13
210000000709 aorta Anatomy 0.000 description 12
241001465754 Metazoa Species 0.000 description 11
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
230000003143 atherosclerotic effect Effects 0.000 description 9
210000002540 macrophage Anatomy 0.000 description 9
230000007115 recruitment Effects 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
239000000203 mixture Substances 0.000 description 7
229940068196 placebo Drugs 0.000 description 7
239000000902 placebo Substances 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
229930006000 Sucrose Natural products 0.000 description 6
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
230000002950 deficient Effects 0.000 description 6
230000008595 infiltration Effects 0.000 description 6
238000001764 infiltration Methods 0.000 description 6
239000008188 pellet Substances 0.000 description 6
239000008194 pharmaceutical composition Substances 0.000 description 6
239000005720 sucrose Substances 0.000 description 6
208000037260 Atherosclerotic Plaque Diseases 0.000 description 5
108010007622 LDL Lipoproteins Proteins 0.000 description 5
102000007330 LDL Lipoproteins Human genes 0.000 description 5
NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 5
210000001765 aortic valve Anatomy 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
235000012000 cholesterol Nutrition 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
229930040373 Paraformaldehyde Natural products 0.000 description 4
230000000879 anti-atherosclerotic effect Effects 0.000 description 4
OGGXGZAMXPVRFZ-UHFFFAOYSA-M dimethylarsinate Chemical compound C[As](C)([O-])=O OGGXGZAMXPVRFZ-UHFFFAOYSA-M 0.000 description 4
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
229950004203 droloxifene Drugs 0.000 description 4
238000011065 in-situ storage Methods 0.000 description 4
108020004999 messenger RNA Proteins 0.000 description 4
229920002866 paraformaldehyde Polymers 0.000 description 4
230000010412 perfusion Effects 0.000 description 4
238000005502 peroxidation Methods 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
238000011160 research Methods 0.000 description 4
210000003291 sinus of valsalva Anatomy 0.000 description 4
210000000329 smooth muscle myocyte Anatomy 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
IUPVFHXEIGLEFF-UHFFFAOYSA-N [4-[2-(3-azabicyclo[2.2.1]heptan-3-yl)ethoxy]phenyl]-[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]methanone Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3C4CCC(C4)C3)=CC=2)C2=CC=C(O)C=C2S1 IUPVFHXEIGLEFF-UHFFFAOYSA-N 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
229960005309 estradiol Drugs 0.000 description 3
235000009200 high fat diet Nutrition 0.000 description 3
238000013508 migration Methods 0.000 description 3
239000002904 solvent Substances 0.000 description 3
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
208000001132 Osteoporosis Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
238000002583 angiography Methods 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
230000003078 antioxidant effect Effects 0.000 description 2
210000002376 aorta thoracic Anatomy 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
230000003628 erosive effect Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
210000000497 foam cell Anatomy 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
238000010191 image analysis Methods 0.000 description 2
239000012442 inert solvent Substances 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000006372 lipid accumulation Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000007505 plaque formation Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000010186 staining Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000007858 starting material Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
210000004291 uterus Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
JWQYZECMEPOAPF-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-2-ol Chemical compound C1=CC=C2CC(O)CCC2=C1 JWQYZECMEPOAPF-UHFFFAOYSA-N 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
102100034613 Annexin A2 Human genes 0.000 description 1
108090000668 Annexin A2 Proteins 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
102000013918 Apolipoproteins E Human genes 0.000 description 1
108010025628 Apolipoproteins E Proteins 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
208000021479 Cardiovascular injury Diseases 0.000 description 1
108010055166 Chemokine CCL5 Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
201000000057 Coronary Stenosis Diseases 0.000 description 1
206010011089 Coronary artery stenosis Diseases 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
239000004365 Protease Substances 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
235000021068 Western diet Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
230000035508 accumulation Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000007854 aminals Chemical class 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000002975 chemoattractant Substances 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
230000001076 estrogenic effect Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
230000001788 irregular Effects 0.000 description 1
125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
239000002609 medium Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000007491 morphometric analysis Methods 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
230000007112 pro inflammatory response Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003642 reactive oxygen metabolite Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000002966 stenotic effect Effects 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
239000006211 transdermal dosage form Substances 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47J—KITCHEN EQUIPMENT; COFFEE MILLS; SPICE MILLS; APPARATUS FOR MAKING BEVERAGES
- A47J47/00—Kitchen containers, stands or the like, not provided for in other groups of this subclass; Cutting-boards, e.g. for bread
- A47J47/02—Closed containers for foodstuffs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Food Science & Technology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Indole Compounds (AREA)

IL12212397A 1996-11-15 1997-11-06 Estrogen agonists / antagonists, their pharmaceutical preparations and their use in the preparation of drugs for the treatment of atherosclerosis IL122123A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US3127396P	1996-11-15	1996-11-15

Publications (2)

Publication Number	Publication Date
IL122123A0 IL122123A0 (en)	1998-04-05
IL122123A true IL122123A (en)	2001-07-24

Family

ID=21858549

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12212397A IL122123A (en)	1996-11-15	1997-11-06	Estrogen agonists / antagonists, their pharmaceutical preparations and their use in the preparation of drugs for the treatment of atherosclerosis

Country Status (17)

Country	Link
US (1)	US6034102A (de)
EP (1)	EP0842661B1 (de)
JP (1)	JP3287793B2 (de)
KR (1)	KR100367793B1 (de)
AT (1)	ATE202702T1 (de)
AU (1)	AU740378B2 (de)
CA (1)	CA2221114C (de)
DE (1)	DE69705480T2 (de)
DK (1)	DK0842661T3 (de)
ES (1)	ES2158452T3 (de)
GR (1)	GR3036455T3 (de)
HU (1)	HU223942B1 (de)
IL (1)	IL122123A (de)
MY (1)	MY114586A (de)
NZ (1)	NZ329174A (de)
PT (1)	PT842661E (de)
ZA (1)	ZA9710292B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL126447A (en) *	1998-10-04	2004-09-27	Vascular Biogenics Ltd	An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
US20050197283A1 (en) *	1998-10-04	2005-09-08	Vascular Biogenics Ltd.	Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
US6331562B1 (en)	1998-12-30	2001-12-18	Signal Pharmaceuticals, Inc.	Compounds and methods for modulation of estrogen receptors
US6291456B1 (en)	1998-12-30	2001-09-18	Signal Pharmaceuticals, Inc.	Compounds and methods for modulation of estrogen receptors
US6593322B1 (en)	1999-03-17	2003-07-15	Signal Pharmaceuticals, Inc.	Compounds and methods for modulation of estrogen receptors
CA2367895A1 (en)	1999-03-17	2000-09-21	Signal Pharmaceuticals, Inc.	Compounds and methods for modulation of estrogen receptors
CO5170459A1 (es) *	1999-06-01	2002-06-27	Pfizer Prod Inc	Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos
EP1113007A1 (de) *	1999-12-24	2001-07-04	Pfizer Inc.	Tetrahydroisochinolin-Verbindungen zur Verwendung als Östrogen-Agonisten/-Antagonisten
AU785199B2 (en) *	2000-06-01	2006-11-02	Watson Pharmaceuticals, Inc.	Transdermal delivery of lasofoxifene
CA2420944A1 (en)	2000-08-30	2002-03-07	Chemocentryx, Inc.	Inhibition of cmv infection and dissemination
TWI303990B (en)	2000-10-17	2008-12-11	Pfizer Prod Inc	New use of estrogen agonists/antagonists for improving vascular health
MXPA03004517A (es)	2000-11-24	2004-03-26	Vascular Biogenics Ltd	Metodos que emplean y composiciones que contienen fosfolipidos oxidados definidos para la prevencion y tratamiento de la arteriosclerosis.
AU2002221116A1 (en) *	2000-12-11	2002-06-24	Takeda Chemical Industries Ltd.	Medicinal compositions having improved water-solubility
WO2002062296A2 (en)	2001-02-02	2002-08-15	Chemocentryx, Inc.	Methods and compositions useful for stimulating an immune response
ATE439131T1 (de) *	2001-08-30	2009-08-15	Chemocentryx Inc	Bicyclische verbindungen als hemmer der chemokin- bindung an us28
AU2005314089B2 (en) *	2004-12-08	2011-03-03	Cedars-Sinai Medical Center	Methods for diagnosis and treatment of Crohn's disease
WO2010048415A1 (en) *	2008-10-22	2010-04-29	Cedars-Sinai Medical Center	Methods of using jak3 genetic variants to diagnose and predict crohn's disease
WO2006109312A2 (en) *	2005-04-15	2006-10-19	Vascular Biogenics Ltd.	Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease
US20100021917A1 (en) *	2007-02-14	2010-01-28	Cedars-Sinai Medical Center	Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
US20100190162A1 (en) *	2007-02-26	2010-07-29	Cedars-Sinai Medical Center	Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2010039931A2 (en) *	2008-10-01	2010-04-08	Cedars-Sinai Medical Center	Methods of using il17rd and il23-il17 pathway genes to diagnose crohn's disease
WO2008137762A2 (en) *	2007-05-04	2008-11-13	Cedars-Sinai Medical Center	Methods of diagnosis and treatment of crohn's disease
US20100015156A1 (en) *	2007-03-06	2010-01-21	Cedars-Sinai Medical Center	Diagnosis of inflammatory bowel disease in children
US8486640B2 (en)	2007-03-21	2013-07-16	Cedars-Sinai Medical Center	Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
WO2008134569A2 (en) *	2007-04-26	2008-11-06	Cedars-Sinai Medical Center	Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
WO2010062960A2 (en)	2008-11-26	2010-06-03	Cedars-Sinai Medical Center	METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
WO2010075579A2 (en)	2008-12-24	2010-07-01	Cedars-Sinai Medical Center	Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
KR20230109779A (ko)	2013-03-27	2023-07-20	세다르스-신나이 메디칼 센터	Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
EP4105236A1 (de)	2013-07-19	2022-12-21	Cedars-Sinai Medical Center	Anti-tl1a (tnfsf15) antikörper zur behandlung von entzündlichen darmerkrankungen
KR20180127416A (ko)	2016-03-17	2018-11-28	세다르스-신나이 메디칼 센터	Rnaset2를 통한 염증성 장 질환의 진단 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3046719C2 (de) *	1980-12-11	1983-02-17	Klinge Pharma GmbH, 8000 München	1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
JPH04312526A (ja) *	1991-04-09	1992-11-04	Fujisawa Pharmaceut Co Ltd	骨疾患治療剤
DE4320898A1 (de) *	1993-06-24	1995-01-05	Denecke Rainer Dr Med Vet	Präparat zur Therapie und Prophylaxe von Erkrankungen, die bei Imbalancen von Plasmalipiden auftreten
US6756388B1 (en)	1993-10-12	2004-06-29	Pfizer Inc.	Benzothiophenes and related compounds as estrogen agonists
US5426123A (en) *	1994-05-11	1995-06-20	Eli Lilly And Company	Method for lowering serum cholesterol with 1,1,2-triphenylbut-1-ene derivatives
US5441986A (en) *	1994-07-19	1995-08-15	Pfizer Inc.	Estrogen agonists as remedies for prostate and cardiovascular diseases
US5552412A (en) *	1995-01-09	1996-09-03	Pfizer Inc	5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis

1997
- 1997-10-21 US US08/955,312 patent/US6034102A/en not_active Expired - Fee Related
- 1997-11-05 DE DE69705480T patent/DE69705480T2/de not_active Expired - Fee Related
- 1997-11-05 EP EP97308862A patent/EP0842661B1/de not_active Expired - Lifetime
- 1997-11-05 ES ES97308862T patent/ES2158452T3/es not_active Expired - Lifetime
- 1997-11-05 PT PT97308862T patent/PT842661E/pt unknown
- 1997-11-05 DK DK97308862T patent/DK0842661T3/da active
- 1997-11-05 AT AT97308862T patent/ATE202702T1/de not_active IP Right Cessation
- 1997-11-06 IL IL12212397A patent/IL122123A/en not_active IP Right Cessation
- 1997-11-13 CA CA002221114A patent/CA2221114C/en not_active Expired - Fee Related
- 1997-11-13 NZ NZ329174A patent/NZ329174A/xx unknown
- 1997-11-13 MY MYPI97005407A patent/MY114586A/en unknown
- 1997-11-14 ZA ZA9710292A patent/ZA9710292B/xx unknown
- 1997-11-14 KR KR1019970060003A patent/KR100367793B1/ko not_active Expired - Fee Related
- 1997-11-14 HU HU9702040A patent/HU223942B1/hu not_active IP Right Cessation
- 1997-11-17 AU AU45237/97A patent/AU740378B2/en not_active Ceased
- 1997-11-17 JP JP31522797A patent/JP3287793B2/ja not_active Expired - Fee Related
2001
- 2001-08-27 GR GR20010401305T patent/GR3036455T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
IL122123A0 (en)	1998-04-05
JP3287793B2 (ja)	2002-06-04
KR19980042432A (ko)	1998-08-17
GR3036455T3 (en)	2001-11-30
NZ329174A (en)	2000-10-27
ZA9710292B (en)	1999-05-17
JPH10147527A (ja)	1998-06-02
ES2158452T3 (es)	2001-09-01
PT842661E (pt)	2001-10-30
HU223942B1 (hu)	2005-03-29
EP0842661B1 (de)	2001-07-04
AU740378B2 (en)	2001-11-01
KR100367793B1 (ko)	2003-04-21
EP0842661A2 (de)	1998-05-20
DE69705480T2 (de)	2001-10-31
DE69705480D1 (de)	2001-08-09
DK0842661T3 (da)	2001-09-24
CA2221114C (en)	2003-10-28
ATE202702T1 (de)	2001-07-15
AU4523797A (en)	1998-05-21
HUP9702040A1 (hu)	2000-11-28
HU9702040D0 (en)	1998-01-28
MY114586A (en)	2002-11-30
EP0842661A3 (de)	1998-09-02
US6034102A (en)	2000-03-07
CA2221114A1 (en)	1998-05-15

Legal Events

Date	Code	Title
2002-02-10	FF	Patent granted
2002-02-10	KB	Patent renewed
2004-01-04	KB	Patent renewed
2008-01-06	KB	Patent renewed
2012-10-31	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
EP0842661B1 (de)	2001-07-04	Verwendung von Oestrogenagonisten und -antagonisten zur Herstellung eines Medikaments zur Behandlung von Atherosklerose, unabhängig von Lipidsenkung
US6114395A (en)	2000-09-05	Method of treating atherosclerosis
EP1940364B1 (de)	2014-06-11	Kapselformulierung von pirfenidon und pharmazeutisch unbedenklichen hilfsstoffen
JPH09505809A (ja)	1997-06-10	ヒドロキシカルバゾール化合物類による平滑筋移動および増殖の阻害
AU2012240864A1 (en)	2013-11-07	Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a CNS disorder
CA2221091C (en)	2002-05-28	Estrogen agonist/antagonists treatment of atherosclerosis
AU4303400A (en)	2000-11-10	Use of saredutant and of its pharmaceutically acceptable salts for the preparation of medicinal products that are useful in the treatment or prevention of major depressive disorders
JPH10101579A (ja)	1998-04-21	ガン治療用および予防用医薬組成物
US5061715A (en)	1991-10-29	Prevention of glycoprotein enveloped virus infectivity by quinolyl- and isoquinolyloxazole-2-zones
KR20240099045A (ko)	2024-06-28	나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 비알코올성 지방간 질환 예방 또는 치료용 약학적 조성물
EA010868B1 (ru)	2008-12-30	Применение производных бицикло[2.2.1]гептана для приготовления нейропротекторных фармацевтических композиций
EP0428105B1 (de)	1994-01-19	Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren
US20050222212A1 (en)	2005-10-06	Compounds and methods
AU2013201986A1 (en)	2013-04-18	Capsule Formulation Of Pirfenidone And Pharmaceutically Acceptable Excipients
JP2001504119A (ja)	2001-03-27	イトラコナゾールおよびヒドロキシイトラコナゾールの副作用を回避するためのｃｉｓ―ヒドロキシイトラコナゾールの使用
JPWO2006051757A1 (ja)	2008-05-29	虚血性心疾患もしくは虚血性心筋症の治療剤または予防剤
HK1117762B (en)	2015-02-06	Capsule formulation of pirfenidone and pharmaceutically acceptable excipients